A PHASE 3 CLINICAL OUTCOMES STUDY TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN SUBJECTS PRESENTING WITH ACUTE CORONARY SYNDROME TREATED WITH LOSMAPIMOD COMPARED TO PLACEBO (LATITUDE-TIMI 60):